Enhancing responses to cancer immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed.

1. Vaccine strategies for cancer prevention in Lynch syndrome: the potential of dendritic cell-based therapy.Familial cancer · 2026
   Review
2. Role of B1 antisense RNA on the proliferation and killing tumor ability of aged mouse spleen lymphocytes.Scientific reports · 2025
   Article
3. Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties.Nature cancer · 2024
   Article
4. Germline mechanisms of immunotherapy toxicities in the era of genome-wide association studies.Immunological reviews · 2023
   Review
5. [Application value of whole exon sequencing and immune related indicators in the precision treatment of oral squamous cell carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023
   Article
6. The germline HLA-A02B62 supertype is associated with a PD-L1-positive tumour immune microenvironment and poor prognosis in stage I lung cancer.Heliyon · 2023
   Article
7. Pinpointing the tumor-specific T cells via TCR clusters.eLife · 2022
   Article
8. Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors.Nature communications · 2021
   Article
9. Vaccines for Non-Viral Cancer Prevention.International journal of molecular sciences · 2021
   Review
10. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.Nature reviews. Clinical oncology · 2021
    Review
11. Reconstructing the tumor architecture into organoids.Advanced drug delivery reviews · 2021
    Review
12. Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches.Cancer discovery · 2021
    Review
13. Loss of natural resistance to schistosome in T cell deficient rat.PLoS neglected tropical diseases · 2020
    Article
14. Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
15. The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.Molecular & cellular proteomics : MCP · 2020
    Article
16. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors.Biomarker research · 2020
    Review
17. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.Nature reviews. Cancer · 2019
    Review
18. DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade.Frontiers in genetics · 2019
    Article
19. Immunomodulating Nanomedicine for Cancer Therapy.Nano letters · 2018
    Review
20. iReceptor: A platform for querying and analyzing antibody/B-cell and T-cell receptor repertoire data across federated repositories.Immunological reviews · 2018
    Review

Corrections and comments

• Comment on
  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.2018

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as